In the proposed randomized double blind cross-over placebo controlled study, the researchers
intend to investigate if Atorvastatin (FDA approved statin for children) can be used to
alleviate the symptom of bone pain (acute phase reaction) that is commonly associated with
initial doses of pamidronate or zoledronic acid, and also the mechanism that underlies this
proposed beneficial effect of Atorvastatin. The primary outcome studied will be alleviation
of bone pain by Atorvastatin compared to placebo by visual analogue pain scale in children
treated with pamidronate or zoledronic acid. The secondary outcome investigated will be
changes in blood count and γδT cell count, C-reactive protein (CRP) and cytokine levels of
interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α) and gamma interferon (γ-IFN)
following treatment with Atorvastatin compared to placebo.